A Phase 2 interventional study of PUR1900 and Placebo in Allergic Bronchopulmonary Aspergillosis, sponsored by Pulmatrix Inc.. Terminated at 20 sites in 5 countries. Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2021-08-27.
Sponsored by Pulmatrix Inc. · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 10 studies in Aspergillosis, Allergic Bronchopulmonary with a site in United States — none open to participants now, none under way, none of them phase 3. Aspergillosis, Allergic Bronchopulmonary · United States.
Among the 10 studies in Aspergillosis, Allergic Bronchopulmonary with a site in United States, this one is one of 2 that started in 2019, is one of 3 in phase 2, and was the 6th registered.
42 studies on the registry are indexed under Aspergillosis, Allergic Bronchopulmonary; 13 are open to participants now.
Browse Aspergillosis, Allergic Bronchopulmonary studies →None of the 10 studies in Aspergillosis, Allergic Bronchopulmonary with a site in United States is open now. The open studies under Aspergillosis, Allergic Bronchopulmonary, anywhere →
Of the 10 Aspergillosis, Allergic Bronchopulmonary studies recruiting now, 7 (70%) set no upper age limit and 1 (10%) stops at 75 or younger; 1 takes children under 18; 2 take healthy volunteers.
This study: 18 Years to 75 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
10 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 1 · Phase 2 4 · Phase 3 2 · Phase 4 1
First in 2005; this study’s year is marked. 2 started in 2019.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 7 is below the median of 58 across 25 interventional studies indexed under Aspergillosis, Allergic Bronchopulmonary.
Median enrollment 35 across the 8 interventional studies, 52 across the 2 observational. Of the 9 that completed or were terminated, 5 (56%) have results posted.
This tab as a report to print or save as PDF → With an account.
6 of 10 have an industry lead sponsor. The 8 most frequent:
Pulmatrix Inc. is the lead sponsor of 15 studies on the registry; none are open to participants now.
Pulmatrix Inc. has 2 studies filed under Aspergillosis, Allergic Bronchopulmonary — fewer than ten, so there is no comparison to draw.
None of the studies under way reaches primary completion within a year.
Among the 10 studies in Aspergillosis, Allergic Bronchopulmonary with a site in United States, from their registry updates:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
A Randomized, Double-Blind, Multicenter, Placebo-Controlled, Phase 2 Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of Itraconazole Administered as a Dry Powder for Inhalation (PUR1900) in Adult Asthmatic Patients With Allergic Bronchopulmonary Aspergillosis
This is a randomized, double-blind, multicenter, placebo controlled, multiple-arm study.
Following screening and confirmation of eligibility, subjects will be randomly assigned (1:1:1:1) into 4 arms of 16 subjects each and will receive 10 mg, 20 mg, or 35 mg of PUR1900 or placebo, administered via dry powder inhalation daily for 28 days. The doses of PUR1900 are stated in this protocol as the respective nominal doses of itraconazole.
Subject eligibility for the study will be determined within 28 days before the first dose of study drug (Day 1) and will be confirmed between 9 and 6 days before dosing and again on Day 1.
Eligible subjects will begin daily dosing with study drug (PUR1900 or placebo) on Day 1.
Subjects will return to the study site for visits on Days 2, 7, 14, and 28 and will be dosed at the study site. The remaining daily doses of study drug will be self-administered at home.
A follow-up visit will occur 7 to 10 days after the last dose of study drug.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
From a breathing test (spirometry): how much air you can blow out in the first second. Often given as a percentage of what is expected for your age, height and sex.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
BMI (body mass index)
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Corticosteroids (steroids)
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
FEV1
From a breathing test (spirometry): how much air you can blow out in the first second. Often given as a percentage of what is expected for your age, height and sex.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Postmenopausal
Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Study drug (PUR1900) will be administered orally, using a Dry Powder Inhaler (DPI) specific to the study (RS01 Monodose inhaler)
Combination Product: PUR1900
Study drug (PUR1900) will be administered orally, using a Dry Powder Inhaler (DPI) specific to the study (RS01 Monodose inhaler)
Combination Product: PUR1900
Study drug (PUR1900) will be administered orally, using a Dry Powder Inhaler (DPI) specific to the study (RS01 Monodose inhaler)
Combination Product: PUR1900
Placebo
Combination Product: Placebo
PUR1900 contains itraconazole as the active ingredient, and it is formulated as a dry powder for oral inhalation.
PUR1900 placebo
Incidence of treatment-emergent adverse events
Time frame: From Day 1 through Follow Up (which is 7 to 10 days after the last dose)
Incidence of intraday FEV1 declines
Time frame: From Day 1 through Follow Up (which is 7 to 10 days after the last dose)
Respiratory rate
Time frame: From Day 1 through Follow Up (which is 7 to 10 days after the last dose)
Blood pressure
Systolic pressure over diastolic pressure
Time frame: From Day 1 through Follow Up (which is 7 to 10 days after the last dose)
Heart rate
Beats per minute
Time frame: From Day 1 through Follow Up (which is 7 to 10 days after the last dose)
Oxygen saturation
As a percentage
Time frame: From Day 1 through Follow Up (which is 7 to 10 days after the last dose)
Physical examination findings
Physician's notes
Time frame: From Day 1 through Follow Up (which is 7 to 10 days after the last dose)
Clinical laboratory test results
Lab reports with any out of range results flagged
Time frame: From Day 1 through Follow Up (which is 7 to 10 days after the last dose)
12-Lead electrocardiogram findings
ECG report and tracing
Time frame: From Day 1 through Follow Up (which is 7 to 10 days after the last dose)
Sputum concentrations of itraconazole and hydroxy-itraconazole
Time frame: Day 2 to Day 28
Sputum eosinophils
Time frame: (Day -9 to Day -6) to Day 28
To evaluate the effect of PUR1900 on pulmonary function following single- and multiple-dose administration of PUR1900
Time frame: Day 1 to Day 28
Asthma Control Questionnaire-6 (ACQ 6)
Scores range between 0 (totally controlled) and 6 (severely uncontrolled).
Time frame: Day 1 to Day 28
Change from baseline (Day 1) to Day 28 in A fumigatus burden in sputum
As assessed by quantitative PCR and sputum culture
Time frame: Day 1 to Day 28
Cmax (maximum observed concentration in plasma)
Time frame: Day 1 to Day 28
Tmax (time to maximum concentration in plasma)
Time frame: Day 1 to Day 28
AUC (area under the concentration-time curve)
Time frame: Day 1 to Day 28
CL/F (clearance)
Time frame: Day 1 to Day 28
Vz/F (apparent volume of distribution)
Time frame: Day 1 to Day 28
Plan to share: No
No publications or documents are linked to this record.
Ran from Jul 2019 to primary completion in Jul 2020, 11 months.
How these figures are worked out, and which studies are left out of them.
This study is terminated, as verified in Jul 2021. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Aspergillosis, Allergic Bronchopulmonary →
Pulmatrix Inc.